Special Issue "Privileged Structures as Leads in Medicinal Chemistry 2023"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3176
Special Issue Editors
Interests: synthesis; inorganic chemistry; medicinal chemistry; biochemistry; bioinorganic chemistry; metal complexes; cancer; phosphine; magnetic delivery system; drug carriers; nanoparticles
Special Issues, Collections and Topics in MDPI journals
Interests: synthesis; inorganic chemistry; medicinal chemistry; bioinorganic chemistry; metal complexes; cancer; phosphine; magnetic delivery system; drug carriers; nanoparticles; cancer drug
Special Issue Information
Dear Colleagues,
Over the past few years, the privileged structure concept has emerged as a fruitful and interesting approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with various binding properties. Single scaffolds, owing to the modification of functional groups, are usually able to provide potent and selective ligands for a range of different biological targets. In addition, privileged structures typically exhibit good drug-like properties, which in turn lead to more drug-like compound libraries and leads. Nobel laureate James Whyte Black said that “the most fruitful basis for the discovery of a new drug is to start with an old”. The use of privileged structure scaffolds in medicinal chemistry embraces James Black’s statement, and despite numerous debates amongst medicinal chemists regarding the validity of the concept within drug discovery, it persists and continues to grow in popularity.
This “Privileged Structures as Leads in Medicinal Chemistry 2023” Special Issue welcomes articles addressing the synthesis, characterization, and application of privileged structures, both in traditional medicinal chemistry and in the design of focused libraries. Work that proposes new strategies that can lead to the discovery of new drugs is also welcome, and the identification as well as use of privileged structures, including molecular fragments that are able to interact with more than one target, are of particular interest.
Dr. Urszula K. Komarnicka
Dr. Sandra Kozieł
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- medicinal chemistry
- privileged structures
- molecular targets
- drugs
- biological activity
